@article{ATM23378,
author = {Jens Juul Holst},
title = {Long-acting glucagon-like peptide-1 receptor agonist—status December 2018},
journal = {Annals of Translational Medicine},
volume = {7},
number = {5},
year = {2019},
keywords = {},
abstract = {Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now included in most guidelines for treatment of type 2 diabetes, most recently in the Consensus Report by the European Society for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) (1). However, it is still just a few percent of the diabetes patients that actually receive GLP-1 RA therapy. This is an interesting paradox which needs serious contemplation.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/23378}
}